Mr. Erez Tetro reports

VVT MED PROVIDES UPDATE ON MANAGEMENT CEASE TRADE ORDER

VVT Med Inc. is providing an update with respect to its previously announced management cease trade order issued by the B.C. Securities Commission under National Policy 12-203 (Cease Trade Orders for Continuous Disclosure Defaults), as previously disclosed in the news releases of the company dated April 17, 2026, May 1, 2026, May 15, 2026, and May 29, 2026.

The company and its auditor continue to work diligently to file the audited financial statements and related annual management's discussion and analysis for the financial year ended Dec. 31, 2025, as required under Part 4 and Part 5, respectively, of National Instrument 51-102 (Continuous Disclosure Obligations), and related certifications of such filings by the company's chief executive officer and chief financial officer as required under Part 4 of National Instrument 52-109 (Certification of Disclosure in Issuers' Annual and Interim Filings). It is expected that the company will be able to complete the required filings by no later than June 29, 2026.

As a result of the delay in filing the required filings, the company was unable to file its interim financial statements for the three months ended March 31, 2026, its related management's discussion and analysis, and related filings by the prescribed deadline. Under National Instrument 51-102, the interim filings were required to be filed by June 1, 2026. The company now anticipates filing the interim filings, together with the required filings, on or before June 29, 2026.

The company is providing this biweekly update in accordance with NP 12-203 and will continue to do so for so long as it remains in default of its obligation to file the required filings.

The company confirms that, as of the date of this news release: (a) there has been no material change to the information set out in the default announcement or the MCTO news releases that has not been generally disclosed; (b) there has been no failure by the company in fulfilling its stated intentions with respect to satisfying the provisions of the alternative information guidelines set out in NP 12-203; (c) there has not been, nor is there anticipated to be, any specified default subsequent to the default which is the subject of the default announcement; and (d) there is no other material information concerning the affairs of the company that has not been generally disclosed.

The MCTO does not affect the ability of shareholders who are not insiders of the company to trade securities of the company. The MCTO prohibits the chief executive officer and the chief financial officer of the company from trading in securities of the company for so long as the required filings are not filed. Additionally, for so long as the required filings are not filed, the company will not, directly or indirectly, issue securities to or acquire securities from an insider or employee of the company except in accordance with legally binding obligations to do so existing as of May 1, 2026.

About VVT Med Inc.

VVT is the only Food and Drug Administration-cleared, stand-alone company offering non-thermal, non-tumescent (NT-NT) varicose vein treatment technology. VVT's catheter-based technologies, ScleroSafe and V-Block, enable safe, office-based procedures with no anesthesia or downtime. Addressing the widest range of vein diameters, VVT's solutions empower physicians to treat both the medical and aesthetic aspects of vein disease through a cost-efficient, simultaneous sclerosant injection and blood aspiration process. The company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038.

We seek Safe Harbor.